These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Interstitial diffusion and the relationship between compartment modelling and multi-scale spatial-temporal modelling of (18)F-FLT tumour uptake dynamics. Liu D; Chalkidou A; Landau DB; Marsden PK; Fenwick JD Phys Med Biol; 2014 Sep; 59(17):5175-202. PubMed ID: 25138724 [TBL] [Abstract][Full Text] [Related]
5. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. Hoeben BA; Troost EG; Span PN; van Herpen CM; Bussink J; Oyen WJ; Kaanders JH J Nucl Med; 2013 Apr; 54(4):532-40. PubMed ID: 23345303 [TBL] [Abstract][Full Text] [Related]
6. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960 [TBL] [Abstract][Full Text] [Related]
7. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329 [TBL] [Abstract][Full Text] [Related]
8. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. Menda Y; Boles Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Schultz MK; Sunderland JJ; Graham MM; Buatti JM J Nucl Med; 2009 Jul; 50(7):1028-35. PubMed ID: 19525472 [TBL] [Abstract][Full Text] [Related]
9. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET for detecting tumor repopulation during fractionated radiotherapy of human FaDu squamous cell carcinoma in nude mice. Yue JB; Yang J; Liu J; Lee J; Cabrera AR; Sun XD; Bai GH; Li YH; Yu JM Radiother Oncol; 2014 Jun; 111(3):475-81. PubMed ID: 24813091 [TBL] [Abstract][Full Text] [Related]
10. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. Kishino T; Hoshikawa H; Nishiyama Y; Yamamoto Y; Mori N J Nucl Med; 2012 Oct; 53(10):1521-7. PubMed ID: 22872738 [TBL] [Abstract][Full Text] [Related]
12. Optimal transformations leading to normal distributions of positron emission tomography standardized uptake values. Scarpelli M; Eickhoff J; Cuna E; Perlman S; Jeraj R Phys Med Biol; 2018 Jan; 63(3):035021. PubMed ID: 29235988 [TBL] [Abstract][Full Text] [Related]
13. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas. Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265 [TBL] [Abstract][Full Text] [Related]
15. Reproducibility of the kinetic analysis of 3'-deoxy-3'-[(18)F]fluorothymidine positron emission tomography in mouse tumor models. Choi SJ; Kim SY; Kim SJ; Lee JS; Lee SJ; Park SA; Lee SJ; Yun SC; Im KC; Oh SJ; Kim SW; Kim JS; Ryu JS; Moon DH Nucl Med Biol; 2009 Oct; 36(7):711-9. PubMed ID: 19720283 [TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787 [TBL] [Abstract][Full Text] [Related]
17. Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. Arens AI; Troost EG; Hoeben BA; Grootjans W; Lee JA; Grégoire V; Hatt M; Visvikis D; Bussink J; Oyen WJ; Kaanders JH; Visser EP Eur J Nucl Med Mol Imaging; 2014 May; 41(5):915-24. PubMed ID: 24346414 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer. Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204 [TBL] [Abstract][Full Text] [Related]
19. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. Grönroos TJ; Lehtiö K; Söderström KO; Kronqvist P; Laine J; Eskola O; Viljanen T; Grénman R; Solin O; Minn H BMC Cancer; 2014 Nov; 14():876. PubMed ID: 25421331 [TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]